Navigation Links
Anthera Announces Completion of Safety Review by DSMB for VISTA-16
Date:12/14/2011

HAYWARD, Calif., Dec. 14, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that the VISTA-16 Data Safety Monitoring Board (DSMB) has met for the fifth time to review available safety data and has recommended the study continue without change.  The Company is awaiting the assessment of a pre-defined interim efficacy analysis of the primary endpoint, which is scheduled to occur after 50% of the primary endpoint events in the VISTA-16 clinical study have been collected, adjudicated and reviewed by the DSMB.  The primary endpoint of the VISTA-16 study is a composite of the time to occurrence of a secondary major adverse cardiovascular event consisting of unstable angina requiring urgent hospitalization, myocardial infarction, stroke and cardiovascular death.

About Varespladib and sPLA2

Varespladib is a potent oral inhibitor of a number of pro-inflammatory enzymes collectively known as secretory phospholipase A2 (sPLA2). Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including ACS, and are associated with an increased risk for future ischemic events, such as a heart attack or even death. In Anthera's FRANCIS Phase 2 clinical study in ACS patients, treatment with varespladib improved independent markers of cardiovascular risk including C-reactive protein, IL-6, LDL-C and varespladib's target enzyme, sPLA2. Recent analysis of data from diabetic patients in the same Phase 2 study demonstrated treatment with varespladib was associated with early and statistically significant reductions in these prognostic inflammatory markers of cardiovascular risk. VISTA-16 is an event driven clinical study evaluating the use of varespladib methyl in combination with Lipitor
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
2. Anthera Pharmaceuticals Reports 2011 Third Quarter Financial Results and Operational Update
3. Anthera Announces Last Patient Enrolled in PEARL-SC Study
4. Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
5. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
6. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
7. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
9. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
10. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
11. Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... selective prostaglandin receptor agonist which effectively reduces intraocular ... by FDA, latanoprost (under the trade name of ...
(Date:8/28/2015)... 2015  Perrigo Company plc ("Perrigo") (NYSE: PRGO ... acquisition of leading OTC brands from GSK in an ... is a clear demonstration of Perrigo,s unique ability to ... network spanning 36 countries.  Perrigo Chairman, ... "We are excited to complete this transaction, which clearly ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... PharMEDium Healthcare Corporation has become an Industry Supporter of ... of a new Corporate Supporter program available to pharmaceutical, ... N. Jonas, PharMEDium Chairman and CEO commented, "We are ... field through leadership, education and research.  As a leading ...
... FAIRFAX, Va., April 11, 2011 General Dynamics ... (NYSE: GD ), has been awarded ... training instrumentation suite into the Vincennes University hospital ... a realistic training environment for the continuing education ...
Cached Medicine Technology:PharMEDium Becomes a Corporate Supporter of the American Society of Anesthesiologists (ASA) 2General Dynamics' InForce™ Training Toolkit to Support Vincennes University Hospital Simulation Lab 2
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health ... and sell Arterosil and Arterosil HP, and that all claims and counterclaims have ... Health Sciences, LLC (VHS) in the United States District Court for the Southern ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a growing number of ... transitioned management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... Malaria Day at the Zoo to celebrate children helping children, a thank you ... congregations throughout West Ohio have contributed to the United Methodist initiative to end ...
(Date:8/28/2015)... ... 2015 , ... An article published August 19th by the LA ... through to open a pizzeria in Westchester. Mr. LaRocco was aware from opening prior ... but the current process, having already gone on for over a year, is taking ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing ... their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart ... They believe that together, a difference can be made. Walkers can participate in the ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2
... a surgical procedure using a cutting-edge super glue pioneered ... recovery of heart patients recovering from open-chest surgery, Dr. ... co-hosted by the Heart and Stroke Foundation and the ... being used to enhance the closure of the breastbone ...
... and Stroke Foundation researcher has discovered what could be ... treatment of pulmonary hypertension, a devastating, life-threatening condition which ... have discovered an early warning system in a protein ... Congress 2010, co-hosted by the Heart and Stroke Foundation ...
... Jenifer Goodwin HealthDay Reporter , FRIDAY, Oct. 22 (HealthDay News) ... Children , where he plays an Iraq War vet with severe burns ... was dead rather than reveal his injuries. Martinez, 27, earned the ... In 2003, just a month into his first Iraq deployment as ...
... immune cells that reside in the brain, have a ... It was previously thought that microglia originated at the ... that are thought to develop at birth. This groundbreaking ... of degenerative brain diseases such as Alzheimer,s and autoimmune ...
... Oct. 22 (HealthDay News) -- Misdiagnosis of pneumonia is ... a hospitalization for the same illness, according to two ... of antibiotics and increased health care costs, said the ... They examined the medical records of 127 patients who ...
... system faces a challenge in overcoming communication barriers ... the University of Gothenburg, Sweden. The thesis ... refugees have found it hard to gain access ... are entitled to. Interpreters were sometimes assigned on ...
Cached Medicine News:Health News:Kryptonite superglue improving the quality of life in heart patients recovering from surgery 2Health News:Quebec City researchers pave the way for novel treatment of pulmonary hypertension 2Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 2Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 3Health News:Mount Sinai researchers discover origin of immune cells in the brain 2Health News:Prior Hospitalization With Pneumonia Often Tied to Later Misdiagnosis 2Health News:Communicating through interpreters -- a challenge for health care 2
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
... Calibrated Guide Wires are available in two ... 9 in. length. Material: DePuy certified stainless ... ,Smooth wires etched in 1/2 in. ... also available. Etched in 1/2 in. ...
Kirschner Wires are available in four point styles ranging from .028 to .062 in. Smooth tip wire available in 4, 6 and 9 in. lengths. Threaded tip available. Material: DePuy certified stainless steel...
... Non-Donor Supplemental: Calypte Biomedical ... HIV-1 antibody testing algorithm as well ... Western Blot Kit [Human Immunodeficiency Virus ... products represent a portfolio of established ...
Medicine Products: